Jun 21 2022

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

By |2022-06-21T05:23:46-04:00June 21st, 2022|Featured, Investor News, News|0 Comments

Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC-PINK: "HALB”) announced the creation of a subgroup of researchers to focus on cancer treatment.  Halberd’s technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer treatments. The subgroup will be guided ...

Jun 8 2022

Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification

By |2022-06-07T21:21:57-04:00June 8th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, June 8, 2022 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd’s patented extracorporeal disease eradication processes.  Consistent with its press release of May 18, 2022, Halberd commenced its pursuits with mdi ...

May 24 2022

Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines

By |2022-05-24T05:22:45-04:00May 24th, 2022|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 24, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine from a homogeneous mixture of two different cytokines in a fluid.  Several adverse health conditions are caused by excess quantities of particular components in blood or ...

Apr 25 2022

Halberd CEO Letter

By |2022-04-24T18:20:33-04:00April 25th, 2022|Featured, Investor News, News, Press Releases, Update Letter|0 Comments

Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked ...

Apr 18 2022

Halberd Eliminates E. coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics

By |2022-04-17T19:16:30-04:00April 18th, 2022|Featured, Investor News, Medical, Press Releases|0 Comments

Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states.  The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes.  This ...

Mar 25 2022

Halberd Corporation Brief Overview

By |2022-03-25T09:57:20-04:00March 25th, 2022|Featured, News|Comments Off on Halberd Corporation Brief Overview

Halberd Corporation Brief Overview Halberd Corporation was re-formed in May 2020.  Noting that Halberd’s unique extracorporeal technological approach is adaptable to many disease states, Halberd’s team of professionals employed its skills, resources and focus to concentrate on developing treatments against some of the world’s more persistent diseases, such as, Alzheimer’s Disease, PTSD, ...

Mar 16 2022

Infectious Disease Specialist Will Guide Halberd’s Extracorporeal Elimination of Disease Antigens in Animals and Then Humans

By |2022-03-15T22:01:14-04:00March 16th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, March 16, 2022 – Halberd Corporation (OTC-PINK: "HALB") announces its entry into the next stage of research.  To guide it, having successfully eliminated the Top 10 Target Antigens associated with neurodegenerative diseases in vitro, Halberd is pleased to announce the addition of Ravi Venkata Durvasula, M.D., a renowned infectious disease specialist and ...

Mar 8 2022

Halberd Expands Its Technical Expertise With the Addition of Microbiology Professor

By |2022-03-07T23:31:23-05:00March 8th, 2022|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 8, 2022 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. Chester R. Cooper has joined its technical team.  Dr. Cooper currently holds the position of Professor, Department of Biological Sciences, at Youngstown State University.  Dr. Cooper has been a valuable resource in Halberd’s work at ...

Mar 1 2022

Halberd’s COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant

By |2022-03-01T10:07:25-05:00March 1st, 2022|Featured, Investor News, Medical, News|0 Comments

Outperforms Approved COVID Antibodies Jackson Center, PA, March 1, 2022 – Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen.  The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies.  The results are shown ...

Feb 22 2022

Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually

By |2022-02-21T18:59:51-05:00February 22nd, 2022|Featured, Investor News, Medical, News, Press Releases|1 Comment

Jackson Center, PA, February 22, 2022 – Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases.  With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens.  See Table Below.  This could lead to ...

Go to Top